Skip to main content

Table 4 Minimal residual disease (MRD) of AJS-positive vs. AJS-negative adult patients on days 15, 29 and 79

From: Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study

Timepoint MRD AJS-positive (n = 5) AJS-negative (n = 33) p-Value (Chi-Square)
D15 < 5% 0 (0%) 22 (71%) 0.019
≥5% 4 (100%) 1 missing 9 (29%) 2 missing
D29 < 5% 0 (0%) 30 (96.8%) < 0.001
≥5% 3 (100%) 2 missing 1 (3.2%) 2 missing
D29 < 0.1% 0 (0%) 21 (67.7%) 0.011
≥0.1% 3 (100%) 2 missing 10 (32.3%) 2 missing
D79 < 0.1% 2 (50%) 26 (89.7%) 0.120
≥0.1% 2 (50%) 1 missing 3 (10.3%) 4 missing
  1. AJS ABL-class or JAK-STAT pathway fusions, D15 Day 15, D29 Day 29, D79 Day 79m, MRD Minimal residual disease